Liver News and Research

RSS

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi.

5 Nov 2009

Study finds oral dimercaptosuccinic acid effective in treating children with autism

Two studies published by the Southwest College of Naturopathic Medicine in the October issue of BMC Clinical Pharmacology investigated the use of oral dimercaptosuccinic acid (DMSA), a prescription medicine approved by the FDA for treating lead poisoning, and used off-label in these studies for treating heavy metal toxicity in children with autism.

5 Nov 2009

Scientists identify molecular disparity between iPS cells and embryonic stem cells

The same genes that are chemically altered during normal cell differentiation, as well as when normal cells become cancer cells, are also changed in stem cells that scientists derive from adult cells, according to new research from Johns Hopkins and Harvard.

5 Nov 2009

NIST researchers to develop a certified reference material to assess C-reactive protein

Searching for a needle in a haystack may seem futile, but it's worth it if the needle is a hard-to-detect protein that may identify a person at high risk of a heart attack circulating within a haystack of human serum (liquid component of blood).

5 Nov 2009

Medivir presents OPERA-1 Phase IIa trial data at the AASLD meeting

Data were presented from the phase IIa trial (OPERA-1) for TMC435 at the ongoing 60th annual meeting of the American Association for the Study of Liver Diseases in Boston, USA.

4 Nov 2009

Alnylam Pharmaceuticals and Roche team up to develop specific RNAi therapeutic products

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has advanced to the RNAi therapeutic collaboration stage of its landmark alliance with Roche formed in 2007.

4 Nov 2009

Osiris Therapeutics reports financial results for the third quarter of 2009

Osiris Therapeutics, Inc., the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its financial results for the third quarter of 2009.

4 Nov 2009

GI and hepatology societies take initiative to evaluate the current medical school curriculum

Due to the increasing complexities of treating digestive diseases, allowing gastroenterological (GI) trainee physicians the opportunity to develop enhanced abilities and experiences in specific disease areas or procedures will be a great benefit to patients, according to a "Report of the Multisociety Task Force on GI Training."

4 Nov 2009

Study results of nucleoside polymerase and protease inhibitor combination therapy for HCV promising

All approved therapy regimens to treat patients with hepatitis C are based on interferon, which must be injected. In this clinical trial to be presented at the annual meeting of the American Association for the Study of Liver Diseases, researchers treated patients - both treatment naive and experienced patients - with a twice daily oral combination therapy of a nucleoside polymerase and protease inhibitor.

4 Nov 2009

Scientists identify compounds that hold promise for treating parasitic infection

Using an unconventional approach that they designed, University of Pittsburgh drug discoverers and their collaborators at Walter Reed Army Institute of Research have identified compounds that hold promise for treating leishmaniasis, a parasitic infection that many consider one of the world's most overlooked diseases.

4 Nov 2009

New strategy to eliminate and eradicate malaria unveiled

Marking its tenth anniversary year, the PATH Malaria Vaccine Initiative (MVI) today unveiled a new strategy that sets the stage for an aggressive push targeting the long-term goal of eliminating and eradicating malaria

4 Nov 2009

Findings may lead to new drug therapies to reduce breast cancer metastasis

Researchers have reduced breast cancer metastasis to bone using an experimental agent to inhibit ROCK, a protein that was found to be over-expressed in metastatic breast cancer.

4 Nov 2009

Scientists identify potential drug target for curing alcohol drinking behavior

A group of drunken fruit flies have helped researchers from North Carolina State and Boston universities identify entire networks of genes-also present in humans-that play a key role in alcohol drinking behavior.

4 Nov 2009

$3.9 million Challenge grant for Thomas Jefferson researchers

Four researchers from Thomas Jefferson University have received $3.9 million in Challenge grant funds as part of the American Recovery and Reinvestment Act.

3 Nov 2009

Interim data from Schering-Plough's narlaprevir Phase IIa study

Schering-Plough Corporation reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.

3 Nov 2009

Hormone deficiency may be the cause for chronic diarrhoea

A common type of chronic diarrhoea may be caused by a hormone deficiency, according to new research published in the November issue of Clinical Gastroenterology and Hepatology.

3 Nov 2009

NIH awards $2 million grant for sickle cell disease research

Researchers at the University of Illinois at Chicago will use a $2 million federal grant to investigate why patients with sickle cell disease experience chronic pain -- and to develop drugs to treat it.

2 Nov 2009

Enzo Biochem announces results of EGS21 clinical trial for treatment of non-alcoholic steatohepatitis

Enzo Biochem Inc. announced today that favorable results of the Company’s clinical trial for treatment of non-alcoholic steatohepatitis (NASH) were presented at the annual meeting of the American Association for the Study of Liver Diseases. The study was a randomized double blind placebo controlled format of EGS21, Enzo’s orally administered beta glucosylceramide formulation, designed to evaluate safety and efficacy of the study drug in patients with NASH and its associated metabolic syndrome.

2 Nov 2009

Avila Therapeutics presents preclinical study data of its AVL-181 HCV protease inhibitor

Avila Therapeutics™, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181. Avila showed that AVL-181 promoted complete viral clearance in vitro when used at clinically-relevant concentrations in combination with other HCV therapies.

2 Nov 2009

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new pre-clinical research findings from its transthyretin (TTR)-mediated amyloidosis (ATTR) program at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (“The Liver Meeting”).

2 Nov 2009

Liver News and Research

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Study finds oral dimercaptosuccinic acid effective in treating children with autism

Scientists identify molecular disparity between iPS cells and embryonic stem cells

NIST researchers to develop a certified reference material to assess C-reactive protein

Medivir presents OPERA-1 Phase IIa trial data at the AASLD meeting

Alnylam Pharmaceuticals and Roche team up to develop specific RNAi therapeutic products

Osiris Therapeutics reports financial results for the third quarter of 2009

GI and hepatology societies take initiative to evaluate the current medical school curriculum

Study results of nucleoside polymerase and protease inhibitor combination therapy for HCV promising

Scientists identify compounds that hold promise for treating parasitic infection

New strategy to eliminate and eradicate malaria unveiled

Findings may lead to new drug therapies to reduce breast cancer metastasis

Scientists identify potential drug target for curing alcohol drinking behavior

$3.9 million Challenge grant for Thomas Jefferson researchers

Interim data from Schering-Plough's narlaprevir Phase IIa study

Hormone deficiency may be the cause for chronic diarrhoea

NIH awards $2 million grant for sickle cell disease research

Enzo Biochem announces results of EGS21 clinical trial for treatment of non-alcoholic steatohepatitis

Avila Therapeutics presents preclinical study data of its AVL-181 HCV protease inhibitor

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News